Comparison Between Propess and Cook Double-balloon Catheter for Cervical Priming
Launched by THE UNIVERSITY OF HONG KONG · May 26, 2024
Trial Information
Current as of February 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two methods, Propess and the Cook double-balloon catheter, to help prepare a woman’s cervix for labor when it isn’t ready. The goal is to see which method is more effective and safer for women who are at term in their pregnancy but have a cervix that is not yet ready for delivery. This trial is currently looking for participants who are healthy, pregnant with one baby, and are having their first child (nulliparous).
To be eligible, women must be at least 37 weeks pregnant and have a Bishop score of less than 7, which means their cervix is not yet favorable for labor. Participants in the trial will receive one of the two methods to help soften and open the cervix, making it easier for labor to start. It's important to note that women with certain medical conditions or previous surgeries may not qualify for this study. If you are interested in learning more about participating, it’s a good idea to talk to your healthcare provider.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Viable singleton pregnancy
- • Cephalic presentation
- • Bishop score \<7
- • At term (\>=37+0 weeks of gestation)
- • Nulliparous women
- Exclusion Criteria:
- • Gestation \<37weeks
- • Multiple pregnancy
- • Bishop score \<7
- • Malpresentation
- • Contraindication to vaginal delivery
- • Previous Caesarean section
- • History of myomectomy
- • Maternal fever
- • Suspected infection
- • Abnormal fetal heart-rate patterns
- • Rupture of membranes
- • Intrauterine growth restriction
- • Not fit for giving consent
- • Allergic to Propess or PGE2
Trial Officials
Yin Fong Leung, MBBS
Principal Investigator
The University of Hong Kong
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0